2.27

0.00% +0.00

After Hours: 2.2501 -0.0199 -0.88%

AN2 Therapeutics Inc (ANTX)

Overview News Price History Financials Discussions Forecast

AN2 Therapeutics Inc stock is currently priced at $2.27, with a 24-hour trading volume of 57,325. It has seen a +0.00% increased in the last 24 hours and a -8.47% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.28 pivot point. If it approaches the $2.23 support level, significant changes may occur.

Previous Close:

$2.27

Open:

$2.28

24h Volume:

57,325

Market Cap:

$67.71M

Revenue:

Net Income/Loss:

$-64.73M

P/E Ratio:

-0.8107

EPS:

-2.8

Net Cash Flow:

$-53.29M

1W Performance:

-6.20%

1M Performance:

-8.47%

6M Performance:

-85.95%

1Y Performance:

-72.58%

1D Range:

$2.25

$2.32

52W Range:

$2.20

$22.22

AN2 Therapeutics Inc Stock (ANTX) Company Profile

Name

AN2 Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650-331-9090

Address

1800 El Camino Real, Suite D, Menlo Park

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ANTX's Discussions on Twitter

AN2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform

AN2 Therapeutics Inc Stock (ANTX) Latest News

AN2 Therapeutics shares target cut by Evercore ISI on delayed trial data - Investing.com Canada

Investing.com Canada

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 - MSN

MSN

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 - MSN

MSN

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Elk Valley Times

Elk Valley Times

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire

Business Wire

ANTX Stock Price and Chart — NASDAQ:ANTX - TradingView

TradingView

AN2 Therapeutics Inc Stock (ANTX) Financials Data

AN2 Therapeutics Inc (ANTX) Net Income 2024

ANTX net income (TTM) was -$64.73 million for the quarter ending December 31, 2023, a -58.05% decrease year-over-year.

AN2 Therapeutics Inc (ANTX) Cash Flow 2024

ANTX recorded a free cash flow (TTM) of -$53.29 million for the quarter ending December 31, 2023, a -59.25% decrease year-over-year.

AN2 Therapeutics Inc (ANTX) Earnings per Share 2024

ANTX earnings per share (TTM) was -$2.82 for the quarter ending December 31, 2023, a +40.02% growth year-over-year.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.